Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea.
OBJECTIVE
The lowest effective dose of proton pump inhibitors (PPI) for prevention of peptic ulcer rebleeding remains unclear. The objective of the present study was to evaluate whether low-dose PPI has a similar efficacy to high-dose i.v. administration for maintaining intragastric pH above 6.


METHODS
Sixty-one patients with bleeding ulcers were randomized into one of three groups after endoscopic hemostasis: pantoprazole 80 mg bolus followed by 8 mg/h; 40 mg, 4 mg/h infusion; and bolus injection of 40 mg every 24 h. Intragastric pH values and rebleeding rates were measured. In addition, pharmacokinetic parameters and association with CYP2C19 polymorphisms and H. pylori infection were assessed.


RESULTS
Mean percentage of time with intragastric pH > 6, and the proportion of patients with pH > 6 for more than 60% of the time were significantly higher in the 40 mg, 4 mg/h infusion group compared to the 40 mg bolus injection. There was no significant difference between the 80 mg, 8 mg/h and the 40 mg, 4 mg/h groups. In the H. pylori (-) group, only 40% of patients that received continuous infusion reached the target pH > 6 for more than 60% of the time; this was significantly lower than the H. pylori (+) group, 87.5% (P = 0.026).


CONCLUSIONS
A continuous infusion, regardless of high or low dose, was more effective for acid suppression than a 40 mg bolus PPI injection in Korea. H. pylori infection was an important factor for the maintenance of an intragastric pH > 6.
Choi
Kee Don
KD
Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Kim
Nayoung
N
Jang
In-Jin
IJ
Park
Young Soo
YS
Cho
Joo Youn
JY
Kim
Jung-Ryul
JR
Shin
Jai Moo
JM
Jung
Hyun Chae
HC
Song
In Sung
IS
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D044466:Asian People; D065731:Cytochrome P-450 CYP2C19; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005745:Gastric Acidity Determination; D016480:Helicobacter pylori / Q000302:isolation & purification; D006489:Hemostatic Techniques; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007723:Korea / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000208:ethnology / Q000382:microbiology; D010438:Peptic Ulcer Hemorrhage / Q000208:ethnology / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D055502:Secondary Prevention; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19